Investing in Intellia Therapeutics and Moderna for Future Growth Opportunities

Fixing faulty genes

Intellia Therapeutics (NASDAQ: NTLA)

Intellia works in the field of CRISPR gene editing, aiming to fix faulty genes for disease treatment. Gene editing could revolutionize the medical industry as it offers potential cures for certain diseases.

CRISPR Therapeutics has already achieved regulatory approval for a CRISPR-based product, setting a positive precedent. Intellia is moving towards product approval for ATTR amyloidosis and HAE treatments, with prospects for revenue growth in the future.

• If trials succeed, Intellia could have two products on the market by the end of the decade.
• Intellia aims to launch new gene-editing programs for future revenue growth.
• The company ended last year with approximately $1 billion in cash, ensuring progress towards its commercial goals.

Intellia's share performance may have declined, but there's room for growth with positive trial data as potential catalysts.

Brighter days ahead

Moderna (NASDAQ: MRNA)

Moderna has seen a significant stock decline but anticipates a positive future with upcoming catalysts. The company is focused on advancing its vaccine products and exploring new areas for revenue growth.

• Moderna expects positive outcomes from its combination influenza-COVID vaccine.
• Regulatory approval for the RSV vaccine mRNA-1345 is a major milestone for Moderna. The vaccine's features and convenience make it a promising candidate for revenue generation.
• The company also plans to file for approval for its seasonal flu vaccine later this year, enhancing its revenue potential.
• Exploring the CMV vaccine market represents a multi-billion-dollar opportunity for Moderna with no current competitors.

Moderna projects a return to sales growth and breakeven by 2026, indicating a positive outlook for the company's performance.

A buying opportunity

The stock declines present an opportunity to invest in Intellia and Moderna for potential long-term growth. Despite the inherent risks in biotech investments, these companies offer innovative technologies and lucrative opportunities for investors.